Filing Flows › Pharma-Bio Serv (PBSV) › Q3 FY26 › vs Q3 FY25
Pharma-Bio Serv (PBSV) Q3 FY26 vs Q3 FY25 (year over year)
Pharma-Bio Serv's revenue rose $373K (+19%) from $2.0M in Q3 FY25 to $2.3M in Q3 FY26.
Pharma-Bio Serv, Q3 FY26: revenue $2.3M (+19% year over year), operating margin -3.1%, net loss $14K, operating cash flow $61K. The chart draws each line against Q3 FY25, the increases inside each band.
Margins
| Q3 FY26 | Q3 FY25 | Change | |
|---|---|---|---|
| Free cash flow margin | 2.5% | 11.9% | -9.4 pts |
Every line
| Line | Q3 FY26 | Q3 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $2.3M | $2.0M | $373K | +19% |
| Other income, net | $61K | $105K | −$44K | -42% |
| Net loss | $14K | $204K | −$190K | -93% |
| Costs & expenses | $2.4M | $2.3M | $134K | +6% |
| Operating costs | $2.4M | $2.3M | $131K | +6% |
| Income tax | $3K | −$5K | $8K | — |
| Cost of revenue | $1.6M | $1.4M | $256K | +18% |
| Operating expenses | $764K | $888K | −$125K | -14% |
| Operating cash sources | $75K | $441K | −$366K | -83% |
| Depreciation & amortization | $14K | $16K | −$2K | -13% |
| Share-based compensation | $9K | $10K | −$1K | -14% |
| Working capital & other | $53K | $415K | −$362K | -87% |
| Net loss absorbed | $14K | $204K | −$190K | -93% |
| Operating cash flow | $61K | $237K | −$176K | -74% |
| Free cash flow (OCF − capex) | $60K | $234K | −$175K | -75% |
| Capital expenditures | $1K | $2K | −$1K | -32% |
Questions
How much did Pharma-Bio Serv's revenue grow year over year in Q3 FY26?
Pharma-Bio Serv's revenue rose $373K (+19%) from $2.0M in Q3 FY25 to $2.3M in Q3 FY26.